HAYWARD, Calif., Dec. 9, 2010 /PRNewswire/ — Anthera
Pharmaceuticals, Inc. (Nasdaq:
ANTH), a biopharmaceutical company developing drugs to treat
serious diseases associated with inflammation, today announced it
will hold a conference call to provide an update on the ongoing
investigation and remediation plans relating to vial problems in
the PEARL-SC clinical study. Conference Call Access:Date:
December 14, 2010Time:
5:00 pm Eastern TimeDomestic Dial-in:
(877) 312-8807International Dial-in:
(253) 237-1190Conference ID:
29519371The slides associated with the call can be accessed by
logging into the live webcast at www.anthera.com.
To access the 24-hour audio replay, U.S. and Canadian
participants may dial (800) 642-1687; international participants
may dial (706) 645-9291. The conference ID for the replay is
29519371. The audio replay will be available until December 21,
2010. This conference call will be webcast live and archived
on Anthera’s website until December 14, 2011, www.anthera.com.
About Anthera Pharmaceuticals
Anthera Pharmaceuticals is a biopharmaceutical company focused
on developing and commercializing products to treat serious
diseases associated with inflammation, including cardiovascular and
autoimmune diseases. Anthera has one Phase 3 clinical program,
A-002, and two Phase 2 clinical programs, A-623 and A-001. A-002
and A-001 inhibit a novel enzyme target known as secretory
phospholipase A2, or sPLA2. Elevated levels of sPLA2 have been
implicated in a variety of acute inflammatory conditions, including
acute coronary syndrome and acute chest syndrome, as well as
chronic diseases such as stable coronary artery disease (CAD).
Anthera’s Phase 2 product candidate, A-623, targets elevated levels
of B-lymphocyte stimulat
‘/>”/>
SOURCE
